$ITOS
iTeos Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020042219 Filed on September 01, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.390M
YoY Change
% of Gross Profit
Research & Development $6.137M $3.902M
YoY Change 57.28%
% of Gross Profit
Depreciation & Amortization $130.0K
YoY Change
% of Gross Profit
Operating Expenses $8.531M $5.995M
YoY Change 42.3%
Operating Profit -$8.531M -$5.995M
YoY Change 42.3%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $12.00K -$47.00K
YoY Change -125.53%
Pretax Income -$7.252M -$5.697M
YoY Change 27.3%
Income Tax -$50.00K $58.00K
% Of Pretax Income
Net Earnings -$7.202M -$5.755M
YoY Change 25.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$205.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.9M
YoY Change
Cash & Equivalents $137.0M $33.26M
Short-Term Investments
Other Short-Term Assets $3.200M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $140.4M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.300M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $4.800M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $140.4M
Total Long-Term Assets $4.800M
Total Assets $145.2M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M
YoY Change
Accrued Expenses $3.360M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.500M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.600M
YoY Change
Total Long-Term Liabilities $4.600M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.500M
Total Long-Term Liabilities $4.600M
Total Liabilities $12.16M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$47.92M -$21.68M
YoY Change
Total Liabilities & Shareholders Equity $145.2M
YoY Change

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$7.202M -$5.755M
YoY Change 25.14%
Depreciation, Depletion And Amortization $130.0K
YoY Change
Cash From Operating Activities -$10.00M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$110.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.110M
YoY Change
NET CHANGE
Cash From Operating Activities -10.00M
Cash From Investing Activities -100.0K
Cash From Financing Activities -1.110M
Net Change In Cash -11.21M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$10.00M
Capital Expenditures -$110.0K
Free Cash Flow -$9.890M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001808865
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q2 us-gaap Cash
Cash
136870000
CY2019Q4 us-gaap Cash
Cash
19868000
CY2020Q2 us-gaap Liabilities
Liabilities
12161000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
687000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-224000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35865000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-36088000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
388415
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
256548
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
388415
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256548
dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1336000
dei Entity File Number
EntityFileNumber
001-39401
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei City Area Code
CityAreaCode
339
CY2019Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
133000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
dei Entity Address Address Line1
EntityAddressAddressLine1
139 Main Street
CY2019Q4 us-gaap Assets Current
AssetsCurrent
26076000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
879000
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
122000
CY2019Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2360000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2917000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30744000
dei Local Phone Number
LocalPhoneNumber
217 0161
CY2019Q4 itos Preferred Stock Tranche Rights Liability
PreferredStockTrancheRightsLiability
5400000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6137000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3902000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11962000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8253000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2394000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2093000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4812000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3862000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
8531000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5995000
us-gaap Operating Expenses
OperatingExpenses
16774000
us-gaap Operating Expenses
OperatingExpenses
12115000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8531000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5995000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16774000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12115000
CY2020Q2 itos Grant Income
GrantIncome
1081000
CY2019Q2 itos Grant Income
GrantIncome
678000
itos Grant Income
GrantIncome
2670000
itos Grant Income
GrantIncome
1442000
CY2019Q2 itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
-488000
itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
1265000
itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
296000
CY2020Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
186000
CY2019Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
155000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
370000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
353000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7252000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5697000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12499000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10099000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-50000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-50000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5755000
us-gaap Net Income Loss
NetIncomeLoss
-12449000
us-gaap Net Income Loss
NetIncomeLoss
-10157000
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
106000
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
106000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
213000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
213000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10302000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6776000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16851000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11982000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-29.49
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-55.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-64.52
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
349290
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185716
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
302919
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185716
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
508000
itos Payments For Initial Public Offering Costs
PaymentsForInitialPublicOfferingCosts
1311000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1055000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12521000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9895000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-10678000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
126633000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
245000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
529000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-72000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
262000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6957000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5226000
CY2019Q1 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
697000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
205000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-267000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4402000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-15839000
CY2019Q2 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
915000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
203000
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
529000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-21675000
CY2020Q1 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
CY2020Q1 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
1195000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-317000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5247000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-38526000
CY2020Q2 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
2994000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
245000
us-gaap Profit Loss
ProfitLoss
-12449000
us-gaap Profit Loss
ProfitLoss
-10157000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
250000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
307000
us-gaap Share Based Compensation
ShareBasedCompensation
536000
us-gaap Share Based Compensation
ShareBasedCompensation
408000
itos Deferred Rent Adjustments
DeferredRentAdjustments
14000
itos Deferred Rent Adjustments
DeferredRentAdjustments
5000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
4962000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-1586000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
238000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
282000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
580000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
376000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-886000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-234000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-852000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1055000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9481000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10658000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
673000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
19000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
121000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
2713000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-794000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
205000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0251
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
102000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22474000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-11000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
184000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
117003000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11206000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19990000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22054000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136993000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33260000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
4189000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
1612000
itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
itos Deferred Ipo Costs In Accounts Payable
DeferredIPOCostsInAccountsPayable
400000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
147000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2019Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
1397000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as the related disclosures of contingent assets and liabilities. Estimates are used to determine the fair value of the preferred stock tranche rights liability and anti-dilution warrants liability, the fair value of profit certificates, common stock and stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, probability of repayment for grants repayable, and uncertain tax positions. Actual results could differ materially from the Company&#8217;s estimates.</p>
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
203000
CY2019Q2 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
21000
CY2019Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
5196000
CY2020Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
4161000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.54
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1700000
CY2020Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
0
CY2019Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
5400000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q1 itos Preferred Stock Tranche Rights Liability
PreferredStockTrancheRightsLiability
0
CY2019Q4 itos Anti Dilution Warrants
AntiDilutionWarrants
0
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3553000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3417000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2302000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2081000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020Q2 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1988000
CY2019Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2683000
CY2020Q2 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
1228000
CY2019Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
1409000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
30000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
119000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3360000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4262000
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
3500000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
9829000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
900000
CY2020Q2 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
198000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
536000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
408000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1387003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2127318
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
59076
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
131867
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3323378
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
716304
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.33
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.20
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
523000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M18D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5938000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
122000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.93
CY2020Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
131867
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0045
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1203000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.92
CY2019Q2 itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
2.38
itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
2.38
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
267000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
918000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25783454
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9822049

Files In Submission

Name View Source Status
0001564590-20-042219-index-headers.html Edgar Link pending
0001564590-20-042219-index.html Edgar Link pending
0001564590-20-042219.txt Edgar Link pending
0001564590-20-042219-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itos-10q_20200630.htm Edgar Link pending
itos-20200630.xml Edgar Link completed
itos-20200630.xsd Edgar Link pending
itos-20200630_cal.xml Edgar Link unprocessable
itos-20200630_def.xml Edgar Link unprocessable
itos-20200630_lab.xml Edgar Link unprocessable
itos-20200630_pre.xml Edgar Link unprocessable
itos-ex311_6.htm Edgar Link pending
itos-ex312_7.htm Edgar Link pending
itos-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending